FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Vext Science, Inc. (the “Issuer”)**

Trading Symbol: **VEXT**

Number of Outstanding Listed Securities:  **70,562,367 Common Shares**

Date: **February 28, 2022**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer, through its wholly owned subsidiaries, is a cannabis producer and brand leader based in Arizona and other key markets throughout the United States. The Issuer is focused on leveraging its core expertise in extraction, manufacturing, cultivation, and marketing both to grow within Arizona and to build a profitable multi-state footprint in the U.S. market.**

1. Provide a general overview and discussion of the activities of management.

**None**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None**

4**.** Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have beenamended or abandoned.

**None**

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship**.**

**None**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None**

8. Describe the acquisition of new customers or loss of customers**.**

**None**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**None**

10. Report on any employee hiring, terminations, or lay-offs with details of anticipated length of layoffs.

**There was a net decrease of 5 employees during the month of February 2022, to 188 in total.**

11.Report on any labour disputes and resolutions of those disputes if applicable**.**

**None**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None**

13**.** Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None**

14. Provide details of any securities issued and options or warrants granted.

**During the month 8,333 RSUs vested for the issuance of 8,333 subordinated voting shares.**

15. Provide details of any loans to or by Related Persons.

**None**

16. Provide details of any changes in directors, officers, or committee members.

**On February 10, 2022, the Company announced the appointment of Mark W. Opzoomer to its Board of Directors effective immediately. Mr. Opzoomer is an experienced public company director and committee chair. Mr. Opzoomer is currently Managing Director at Bond Capital Partners, a mid-market private equity investor and advisory firm, which he founded in 2004. Mr. Opzoomer is also currently Chairman of Trint Limited (SaaS AI media creation workflow platform) and a director of the Mark'ennovy group (R&D driven custom contact lens maker and marketer).**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws**

**The concepts of “medical cannabis” and “retail cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marijuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Issuer of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Issuer. Any such proceedings brought against the Issuer may adversely affect the Issuer’s operations and financial performance.**

**COVID-19**

**The Issuer may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact the Issuer by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Issuer may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Issuer is subject. Although the Issuer has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Issuer’s operations will continue to be deemed essential and/or will continue to be permitted to operate. The Issuer may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition, and the trading price of the Issuer’s Common Shares.**

* **Certificate Of Compliance:**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is following the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **March 7, 2022**

 **Eric Offenberger**Name of Director or Senior Officer

**Chief Executive Officer**
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerVext Science, Inc. | For Month EndFebruary, 2022 | Date of ReportYY/MM/DD22/03/07 |
| Issuer Address2250 – 1055 West Hastings Street |
| City/Province/Postal CodeVancouver, British Columbia, V6E 2E9 | Issuer Fax No.(778) 329-9361 | Issuer Telephone No.(604) 688-9588 |
| Contact NameEric J. Offenberger | Contact PositionCEO/COO | Contact Telephone No.(713) 725-4663 |
| Contact Email AddressEric@VextScience.com | Web Site Address[www.VextScience.com](http://www.VextScience.com) |